|Videos|August 12, 2021

Dr. Susan Slovin summarizes state of PARP inhibitor use in prostate cancer

Susan F. Slovin, MD, PhD, summarizes the key points urologists need to know about how PARP inhibitors are currently used in the prostate cancer paradigm.

Susan F. Slovin, MD, PhD, medical oncologist, associate vice chair, Academic Administration, Department of Medicine, Memorial Sloan Kettering Cancer Center, provides a concise summary of the latest information on the state of PARP inhibitors for the treatment of patients with prostate cancer.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.


Latest CME